REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.36
Bid: 1.36
Ask: 1.38
Change: -0.02 (-1.45%)
Spread: 0.02 (1.471%)
Open: 1.36
High: 1.36
Low: 1.36
Prev. Close: 1.38
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: RTW Venture Fund (RTW) - Initiation: 'One-stop shop' for biotech lifecycle investment

12 Jan 2022 08:05

Edison Investment Research Limited Edison Investment Research Limited: RTW Venture Fund (RTW) - Initiation: 'One-stop shop' for biotech lifecycle investment 12-Jan-2022 / 08:05 GMT/BST


 

London, UK, 12 January 2021

 

RTW Venture Fund (RTW) - Initiation: 'One-stop shop' for biotech lifecycle investment

RTW Venture Fund (RTWVF) is managed by healthcare specialist RTW Investments (RTW), which was founded in 2009 by Dr Roderick Wong. It has an innovative approach, focusing on attractive individual assets rather than on companies, so it engages across the corporate lifecycle, from business formations through to investing in much larger listed biotech and medtech companies. RTW is focused on identifying and developing next-generation therapies to significantly improve patients' lives. Since launch, RTWVF's number of investments in private companies has accelerated and the manager is very excited by the global opportunities available.

 

RTWVF provides investors with broad exposure to the global biotech (c 85% of the fund) and medtech (c 15%) sectors. Since inception in late October 2019, the fund has outpaced the performance of both small- and large-cap biotech indices. Its approach of being science-based and a full lifecycle investor, including early-stage, means that the manager is constantly adding to its knowledge bank. RTWVF is prepared to build businesses around attractive assets and supports investee companies as they mature, via a range of financing options. Holdings in private companies are often maintained following their initial public offerings (IPOs) to ensure maximum value is realised, while RTWVF also invests in companies that are already public. RTW has announced it is setting up regional offices in the UK and Shanghai, which should broaden the fund's opportunity set.

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Sarah Godfrey +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn www.linkedin.com/company/edison-group-/

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1267706 12-Jan-2022 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
14th May 20247:00 amRNSMonthly Valuation Update and Factsheet
1st May 20247:01 amRNSTotal Voting Rights
1st May 20247:00 amRNSTransaction in Own Shares
26th Apr 20247:00 amRNSTransaction in Own Shares
25th Apr 20244:46 pmRNSAnnual Financial Report
24th Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20249:30 amRNSNotice of AGM
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20247:00 amRNSMonthly Valuation Update and First Quarter Letter
12th Apr 20245:42 pmRNSPortfolio Company Update: Artios Pharma
12th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
5th Apr 202410:00 amRNSNew Investment: Obsidian Therapeutics
5th Apr 20247:01 amRNSTransaction in Own Shares
4th Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20247:01 amRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 20247:01 amRNSTransaction in Own Shares
28th Mar 20247:00 amRNSAnnual Financial Report
27th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
19th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:01 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSMonthly Valuation Update & Factsheet
11th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSClosed Period Notification
22nd Feb 20243:00 pmRNSDirector/PDMR Shareholding
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20243:54 pmRNSHolding(s) in Company
20th Feb 20245:47 pmRNSPost-transaction Manager NAV Estimate
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20244:50 pmRNSHolding(s) in Company
16th Feb 20249:45 amRNSHolding(s) in Company
14th Feb 20247:01 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSMonthly Valuation Update, January Factsheet
13th Feb 20248:11 amRNSCompletion of Acquisition
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20247:01 amRNSTransaction in Own Shares
9th Feb 20247:00 amRNSRTW Biotech Opp. – Investment Update: Kyverna IPO
1st Feb 20247:00 amRNSTotal Voting Rights
31st Jan 20247:00 amRNSTransaction in Own Shares
30th Jan 20247:00 amRNSUpdate on Arix Transaction
24th Jan 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.